Candida auris in Austria—What Is New and What Is Different
Journal of Fungi · 17.01.2023 · 9 (2) · 129
DOI: 10.3390/jof9020129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 17.01.2023. Verfasst von Kathrin Spettel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Candida auris is a novel and emerging pathogenic yeast which represents a serious global health threat. Since its first description in Japan 2009, it has been associated with large hospital outbreaks all over the world and is often resistant to more than one antifungal drug class. To date, five C. auris isolates have been detected in Austria. Morphological characterization and antifungal susceptibility profiles against echinocandins, azoles, polyenes and pyrimidines, as well as the new antifungals ibrexafungerp and manogepix, were determined. In order to assess pathogenicity of these isolates, an infection model in Galleria mellonella was performed and whole genome sequencing (WGS) analysis was conducted to determine the phylogeographic origin. We could characterize four isolates as South Asian clade I and one isolate as African clade III. All of them had elevated minimal inhibitory concentrations to at least two different antifungal classes. The new antifungal manogepix showed high in vitro efficacy against all five C. auris isolates. One isolate, belonging to the African clade III, showed an aggregating phenotype, while the other isolates belonging to South Asian clade I were non-aggregating. In the Galleria mellonella infection model, the isolate belonging to African clade III exhibited the lowest in vivo pathogenicity. As the occurrence of C. auris increases globally, it is important to raise awareness to prevent transmission and hospital outbreaks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
ORCID-Profile: Kathrin Spettel, Richard Kriz, Iris Camp, Heimo Lagler, Birgit Willinger
Zitieren
APA
Spettel, K., Kriz, R., Wu, C., Achter, L., Schmid, S., Galazka, S., Selitsch, B., Camp, I., Makristathis, A., Lagler, H., & Willinger, B. (2023). Candida auris in Austria—What Is New and What Is Different. Journal of Fungi, 9(2), 129. https://doi.org/10.3390/jof9020129
Vancouver
Spettel K, Kriz R, Wu C, Achter L, Schmid S, Galazka S, et al. Candida auris in Austria—What Is New and What Is Different. Journal of Fungi. 2023;9(2):129. doi:10.3390/jof9020129
BibTeX
@article{Spettel2023,
author = {Spettel, Kathrin and Kriz, Richard and Wu, Christine and Achter, Lukas and Schmid, Stefan and Galazka, Sonia and Selitsch, Brigitte and Camp, Iris and Makristathis, Athanasios and Lagler, Heimo and Willinger, Birgit},
title = {Candida auris in Austria—What Is New and What Is Different},
journal = {Journal of Fungi},
year = {2023},
volume = {9},
number = {2},
pages = {129},
doi = {10.3390/jof9020129}
}
EUVIMED